Skip to main content

Evkeeza News

FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Young Children with Ultra-Rare Form of High Cholesterol

TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza...

FDA Approves Evkeeza (evinacumab-dgnb) for Patients with Homozygous Familial Hypercholesterolemia

TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved Evkeeza (evinacumab-dgnb) as an...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

High Cholesterol - Familial Homozygous

Evkeeza patient information at Drugs.com